Clinical Trials Browser

Phase 2/3 × Fluorouracil × Head & Neck × Clear all

NCT02135042 2026-03-18

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

Phase 2/3 Active not recruiting

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT05125055 2023-11-22

Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC

Phase 2/3 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT05433597 2022-06-27

A Two-blinded, Multicentre, Phase II/III RCT of Concurrent Chemo-radiotherapy Combined or Not Combined With TNF as the Therapy for LA-NPC

Phase 2/3 Not yet recruiting

Nasopharyngeal Carcinoma

NCT04890522 2021-05-18

An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC

Phase 2/3 Not yet recruiting

Nasopharyngeal Carcinoma, Neoplasm Metastasis

NCT00261703 2012-05-11

Docetaxel in Head and Neck Cancer

Phase 2/3 Completed

Head and Neck Neoplasms

NCT00401323 2011-01-20

Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2/3 Completed

Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasm Recurrence, Local